Clinical Oncology Next Generation Sequencing-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Clinical Oncology Next Generation Sequencing

• 1.1 Definition of Clinical Oncology Next Generation Sequencing in This Report
• 1.2 Commercial Types of Clinical Oncology Next Generation Sequencing
  • 1.2.1 Whole Genome Sequencing
  • 1.2.2 Whole Exome Sequencing
  • 1.2.3 Targeted Sequencing & Resequencing Centrifuges
• 1.3 Downstream Application of Clinical Oncology Next Generation Sequencing
  • 1.3.1 Hospitals
  • 1.3.2 Clinics
  • 1.3.3 Laboratories
• 1.4 Development History of Clinical Oncology Next Generation Sequencing
• 1.5 Market Status and Trend of Clinical Oncology Next Generation Sequencing 2016-2026
  • 1.5.1 Global Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026
  • 1.5.2 Regional Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Clinical Oncology Next Generation Sequencing 2016-2021
• 2.2 Production Market of Clinical Oncology Next Generation Sequencing by Regions
  • 2.2.1 Production Volume of Clinical Oncology Next Generation Sequencing by Regions
  • 2.2.2 Production Value of Clinical Oncology Next Generation Sequencing by Regions
• 2.3 Demand Market of Clinical Oncology Next Generation Sequencing by Regions
• 2.4 Production and Demand Status of Clinical Oncology Next Generation Sequencing by Regions
  • 2.4.1 Production and Demand Status of Clinical Oncology Next Generation Sequencing by Regions 2016-2021
  • 2.4.2 Import and Export Status of Clinical Oncology Next Generation Sequencing by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Clinical Oncology Next Generation Sequencing by Types
• 3.2 Production Value of Clinical Oncology Next Generation Sequencing by Types
• 3.3 Market Forecast of Clinical Oncology Next Generation Sequencing by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Clinical Oncology Next Generation Sequencing by Downstream Industry
• 4.2 Market Forecast of Clinical Oncology Next Generation Sequencing by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Clinical Oncology Next Generation Sequencing

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Clinical Oncology Next Generation Sequencing Downstream Industry Situation and Trend Overview

Chapter 6 Clinical Oncology Next Generation Sequencing Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Clinical Oncology Next Generation Sequencing by Major Manufacturers
• 6.2 Production Value of Clinical Oncology Next Generation Sequencing by Major Manufacturers
• 6.3 Basic Information of Clinical Oncology Next Generation Sequencing by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Clinical Oncology Next Generation Sequencing Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Clinical Oncology Next Generation Sequencing Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Clinical Oncology Next Generation Sequencing Major Manufacturers Introduction and Market Data

• 7.1 Illumina, Inc.
  • 7.1.1 Company profile
  • 7.1.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.1.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Illumina, Inc.
• 7.2 Thermo Fisher Scientific
  • 7.2.1 Company profile
  • 7.2.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.2.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific
• 7.3 F. Hoffmann-La Roche Ltd.
  • 7.3.1 Company profile
  • 7.3.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.3.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
• 7.4 Agilent Technologies
  • 7.4.1 Company profile
  • 7.4.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.4.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Agilent Technologies
• 7.5 Myriad Genetics
  • 7.5.1 Company profile
  • 7.5.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.5.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Myriad Genetics
• 7.6 Beijing Genomics Institute (BGI)
  • 7.6.1 Company profile
  • 7.6.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.6.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Beijing Genomics Institute (BGI)
• 7.7 Perkin Elmer
  • 7.7.1 Company profile
  • 7.7.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.7.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Perkin Elmer
• 7.8 Foundation Medicine
  • 7.8.1 Company profile
  • 7.8.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.8.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Foundation Medicine
• 7.9 Pacific Bioscience
  • 7.9.1 Company profile
  • 7.9.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.9.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Pacific Bioscience
• 7.10 Oxford Nanopore Technologies Ltd.
  • 7.10.1 Company profile
  • 7.10.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.10.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Oxford Nanopore Technologies Ltd.
• 7.11 Paradigm Diagnostics
  • 7.11.1 Company profile
  • 7.11.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.11.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Paradigm Diagnostics
• 7.12 Caris Life Sciences
  • 7.12.1 Company profile
  • 7.12.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.12.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Caris Life Sciences
• 7.13 Partek, Inc.
  • 7.13.1 Company profile
  • 7.13.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.13.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Partek, Inc.
• 7.14 Eurofins Scientific S.E.
  • 7.14.1 Company profile
  • 7.14.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.14.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Eurofins Scientific S.E.
• 7.15 Qiagen N.V.
  • 7.15.1 Company profile
  • 7.15.2 Representative Clinical Oncology Next Generation Sequencing Product
  • 7.15.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Qiagen N.V.

Chapter 8 Upstream and Downstream Market Analysis of Clinical Oncology Next Generation Sequencing

• 8.1 Industry Chain of Clinical Oncology Next Generation Sequencing
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Clinical Oncology Next Generation Sequencing

• 9.1 Cost Structure Analysis of Clinical Oncology Next Generation Sequencing
• 9.2 Raw Materials Cost Analysis of Clinical Oncology Next Generation Sequencing
• 9.3 Labor Cost Analysis of Clinical Oncology Next Generation Sequencing
• 9.4 Manufacturing Expenses Analysis of Clinical Oncology Next Generation Sequencing

Chapter 10 Marketing Status Analysis of Clinical Oncology Next Generation Sequencing

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources